October 2020 Vol. 8 No.10

Abstract
Full text
Reprint (PDF) (373 KB)

Search Pubmed for articles by:
 

Case Report

Imatinib Induced Bullous Pemphigoid as a Late Toxicity: A possible Need for Post Treatment Follow-Up?

Walid Shalata^1*, Ala Eddin Neime^1*, Abu Saleh Omar³ , Roxana D. Grinberg¹, Ismaell Massalh¹, Alexander Yakobson¹, Itai Levy¹, Lior Zeller¹

¹The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center; Ben-Gurion University, Beer-Sheva, Israel.
²Department of Internal Medicine, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel.
³Department of Dermatology and Venereology, The Emek Medical Centre, Afula, Israel.

*Corresponding Author's Email: walid.shalata@gmail.com
Cell: +972 (0)54 2967100

Received: 28 August 2020  I  Accepted: 16 September 2020  I  Published: 25 October 2020  I  Article ID: MRJMMS-20-137
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0.

Abstract

The novel use of Tyrosine Kinase Inhibitors (TKI´s) has shown to be a major breakthrough in the treatment of Chronic Myeloid Leukemia (CML). It has opened the doors for TKIs use in a series of neoplasms with success rates previously unheard of. Nevertheless, its use is not free of adverse effects. Skin, gastro-intestinal and central nervous systems arethe most affected, among which autoimmune response can be observed with a higher incidenceintreated populations. Here we report the case of a patient who presented a rare autoimmune disease, bullous pemphigoid, which wasn’t described before as one of the adverse effects (early or late), most probably as a therapy-related adverse effect two years after stopping Imatinib® treatment.

Keywords: Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKI's), Bullous Pemphigoid (BP), Imatinib